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Frequency dependence of compliance (FDC) reflects non-homogeneous ventilatory distribution and, in the
presence of a normal measured airway resistance, suggests peripheral airways dysfunction. This study evaluated
peripheral airway function and bronchial reactivity in irritant exposed or non-exposed individuals with normal
routine pulmonary function tests (PFTs) who had persistent unexplained lower respiratory symptoms.
Twenty-two patients were identified with persistent respiratory symptoms and with normal chest X-ray and
PFTs. Twenty were non-smokers; two had stopped smoking more than 10 years before evaluation. Twelve patients
had been exposed to irritants in their workplaces or at home. Non-specific bronchial hyper-reactivity (nsBHR) and
FDC, pre- and post-bronchodilator, were measured in all patients. Studies were repeated in 6/12 irritant-exposed
subjects after exposure removal and inhaled corticosteroid treatment.
Whereas 12/22 patients had nsBHR, all 22 subjects demonstrated FDC [dynamic lung compliance/static lung
compliance Cdyn,1 / Cst,1 at respiratory frequency 60 min
71 (f60), mean 46%, range 27–67%]. After bronchodilator
administration, a 15% improvement Cdyn,1 was observed most consistently at f60 (mean% improvement 26%, 95%
CI 14–38%) and in subjects without nsBHR. However, Cdyn,1 at f60 did not return to normal after inhaled
bronchodilator. Irritant-exposed and unexposed individuals appeared similar in results of testing for FDC and
nsBHR.
FDC and its response to bronchodilators provide objective physiological measures of an airway abnormality
which may provide a basis for clinical symptoms in patients with normal routine pulmonary function studies. The
presence of persistently abnormal FDC after bronchodilator (BD) and on follow up studies may reflect chronic
inflammatory and/or structural changes in the airways in addition to bronchoconstriction.
Key words: bronchial reactivity; lung compliance; lung diseases, obstructive; irritants; respiratory function tests;
asthma; adrenergic beta-agonists.
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Abnormal peripheral airways resistance may not be
apparent on routine pulmonary function tests (spirometry
and plethysmography). Frequency dependence of compli-
ance (FDC) reflects non-homogeneous ventilatory distribu-
tion and, in the presence of a normal measured airway
resistance, suggests peripheral airways dysfunction (1–3).
FDC has been reported in smokers, the elderly and patients
with chronic obstructive lung disease (including asthma)
(2,4–9). Inhalation of respiratory toxicants can cause a
spectrum of lesions and dysfunction at dierent levels of theReceived 7 June 1999 and accepted in revised form 5 October 1999.
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0954-6111/00/030221+07 $35?00/0respiratory tract, which depends on the severity of the
exposure and on individual factors (10,11). It has been
demonstrated histologically that small airway damage can
result from such exposures (12–14) and abnormal FDC has
been reported in radiographically evident coal workers’
pneumoconiosis (15), short-term exposure to asbestos
(16) and isolated case reports of inhalation injury caused
by nitrogen dioxide (17) and ammonia (18,19). Despite
these considerations, the requirement for esophageal
manometry has limited the use of this test. In addition,
while FDC has been absent in the asymptomatic non-
smoking individuals of several studies (1,5,7,9,15,20), it has
been observed in selected asymptomatic individuals of
other studies and its role in clinical diagnosis of lung
diseases remains unclear.
The primary aim of this study was to evaluate peripheral
airway function and non-specific bronchial hyper-reactivity
(nsBHR) in irritant-exposed or non-exposed, non-smoking,
previously healthy individuals with normal pulmonary# 2000 HARCOURT PUBLISHERS LTD
222 R. E. DE LA HOZ ET AL.function tests who had persistent, unexplained respiratory
symptoms. Secondary aims included: 1. to assess the acute
response of FDC to inhaled bronchodilator and 2. to
evaluate the response of FDC to exposure removal and
inhaled corticosteroid treatment in irritant-exposed patients.
Methods
The protocol for this study was approved by our
institution’s ethics committee and informed consent was
obtained for participation in the study.
SUBJECTS
Subjects were recruited from referrals to the Chest Service
at Bellevue Hospital from December, 1993 to January,
1997. Of all patients referred from the Occupational
Medicine and Primary Care Asthma Clinics, 32 patients
were identified with persistent and unexplained respiratory
symptoms (cough, exertional dyspnoea, chest tightness and/
or wheezing) whose chest radiographs spirometry, lung
volumes and specific conductance were within normal
limits. Premorbid medical records were reviewed in every
patient to exclude subjects with diagnoses of lung disease
predating irritant exposure or current symptoms. Subjects
were limited to those who were lifetime non-smokers or
who had stopped smoking more than 10 years before
evaluation. Based on the above criteria, the study group
consisted of 22 of these 32 patients.
Table 1 summarizes several demographic and clinical
characteristics of the 22 subjects. Although symptoms were
frequently disruptive, most patients were able to continue
their normal daily activities. Twelve patients had been
exposed to irritants in the workplace (n=10) or at home
(n=2), but the intensity and duration of the exposures
varied widely. Clinical histories of all 12 irritant exposed
patients suggested that their symptoms were related to the
irritant exposures. Three of the patients met criteria for a
diagnosis of reactive airways dysfunction syndrome
(RADS) (21). Their single-episode high-level exposure had
taken place 2–24 months before our evaluation. In contrast,
for those who were exposed at home (n=2), the exposures
had taken place for several years at low levels. The irritantsTABLE 1. Characteristics of the 22 study patients*
Age, years 38+10
Female/Male, n 15/7
Symptoms, n
Dyspnea 14
Cough 13
Wheezing 2
Symptom duration, months 22+16
Smoking status, n
Lifetime non-smoker 20
Former smoker (410 yr) 2
*Data are provided as counts (n) or means+1SD.included ammonia, acetic acid, glutaraldehyde, perchloro-
ethylene and other organic solvents, sodium hypochlorite
and other cleaning agents, and triethylene tetramine.
PULMONARY FUNCTION TESTING
Spirometry, lung volumes and specific airway conductance
were measured with a plethysmograph (P.K. Morgan,
Andover, MA, U.S.A.). Measured parameters were refer-
enced to previously published prediction equations (22–26).
Non-specific bronchial hyperreactivity (nsBHR) was
assessed by methacholine challenge (27) (19/22 patients)
or cold-air and exercise challenge (28) (3/22). A 20%
decrease in FEV1 with a nebulized methacholine concen-
tration (PC20) of 8 mg/dl or less, or after cold air breathing
and exercise challenge, was considered a positive test.
Static and dynamic compliance of the lung were
measured with a plethysmograph (P.K. Morgan). Esopha-
geal manometry was performed utilizing an esophageal
balloon (Ackrad Laboratories; Cranford, NJ, U.S.A.)
positioned in the distal third of the esophagus. Elastic
recoil of the lung (Pel) was assessed at TLC using a quasi-
static technique. Static compliance (Cst,1) was measured
with an interrupter technique after three vital capacity
maneuvers (2). Dynamic compliance (Cdyn,1) was deter-
mined at increasing respiratory rates including the patient’s
baseline frequency, 40 breaths min71 and 60 breaths min71
(fBL, f40 and f60, respectively). Tidal volume was
monitored at all frequencies and did not vary by more
than+50 ml. Prior to measurements at each respiratory
frequency, patients were instructed to relax and exhale to
their resting lung volume. Constancy of Cdyn,1 during
successive breaths at each frequency provided evidence that
changes in FRC did not aect the results. Albuterol was
administered by metered-dose inhaler to 19/22 patients and
measurements of Cdyn,1 were repeated over the full range of
frequencies. For all measures of elastic recoil pressure and
lung compliance, data are presented as the mean value from
three reproducible maneuvers.
In order to assess the response of the physiological
abnormalities to treatment, follow-up evaluation was
performed in 6/12 irritant exposed subjects at least 6
months after complete removal (5/6) from or significant
reduction (1/6) of exposure. Treatment consisted of an
inhaled corticosteroid (triamcinolone acetonide 0.8 mg
day71) with or without inhaled b2-agonist.
STATISTICAL ANALYSIS
Data were stored and analysed using an SPSS statistical
program (29). Fisher’s exact test was performed for
bivariate analysis of categorical variables. Unpaired t-tests
or, when data distribution was not normal, Mann–Whitney
U-tests were used to compare group means of continuous
variables. Paired t-tests or, where appropriate, Wilcoxon
signed ranks tests were used to compare within-individual
lung compliance measurements. Two-tailed tests were
performed using an a level of 0.05 to determine statistical
significance. The Bonferroni procedure was used to adjust
FIG. 1. Measurements of dynamic compliance (Cdyn,1),
expressed as percentage of Cst,1, at each respiratory
frequency are plotted for each individual in the study.*:
irritant unexposed patient, with nsBHR; *: irritant
unexposed patient, without nsBHR; ~: irritant exposed
patient, with nsBHR;~: irritant exposed patient, without
nsBHR.
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bronchodilator is calculated for each respiratory frequency
as the % change in Cdyn,1=(Cdyn,1 post-bronchodilator
7Cdyn,1 pre-bronchodilator)/Cdyn,1 pre-bronchodilator.
Response of FDC to bronchodilator was analysed by two
methods: 1. as a continuous variable, by paired comparison
of pre- and post-BD values; and 2. as a categorical variable,
by utilizing an a priori cuto point of 15% improvement to
define a positive response (31).
Results
Table 2 presents the pulmonary function data obtained in
the 22 patients studied. By design, lung volumes, flow rates
and specific conductance were within normal limits for all
subjects. Elastic recoil (Pel) at TLC and Cst,1 were also
normal in all subjects.
Whereas 12/22 patients had nsBHR (including the three
subjects with RADS), all 22 subjects demonstrated fre-
quency dependence of compliance (Fig. 1). FDC expressed
itself at respiratory rates ranging from the baseline rate
(fBL, mean 22 min71) to f60 (Fig. 1). Paired testing
confirmed that the compliance changed significantly with
frequency (Cdyn,1 at fBL, f40 and f60 compared with Cst,1,
P50001 for each). Cdyn,1/Cst,1 at f60 was less than 67% in
all subjects with a mean value of 46%+21% (mean+SD).
Figure 2 illustrates the mean values (+SE) for Cdyn,1 pre-
and post-bronchodilator at each respiratory frequency
studied in 19 of the 22 patients. There was a post-
bronchodilator improvement in Cdyn,,1 at each frequency.
Paired analyses revealed that the change in Cdyn,1 post-
bronchodilator for the group was statistically significant at
f40 (mean 25%, 95% CI 9–41%, P50001) and at f60
(mean 26%, 95% CI 14–38%, P50001), but not at fBL
(mean 11%, 95% CI 72%–24%, P=026). A 15%
improvement in Cdyn,1 after bronchodilator was observed
in 6/19 at fBL, 10/19 at f40 and 11/19 at f60. Values for
Cdyn,1 at f60 remained abnormal post-bronchodilator in all
subjects (Fig. 2). Of note, 5/19 subjects demonstrated a
paradoxical decrease in Cdyn,1 after bronchodilator at fBL
(range of % change 76% to 714%).
Response of Cdyn,1 to bronchodilator was assessed in 10
of the 12 subjects with nsBHR, and nine of the 10 subjectsTABLE 2. Results of pulmonary function test in 22 study
patients*
FEV1, % predicted 102+15
FVC, % predicted 102+17
FEV1/FVC, % 86+5
_V50, % predicted 111+24
TLC, % predicted 99+15
SGAW, (cm H2Os)71 024+010
Pel at TLC, cm H2O 30+8
Cst,1, l cm
71 H2O 0174+0045
*Data are provided as means+1SD. _V50: Flow at 50% of
the vital capacity.without nsBHR. A statistically significant inverse associa-
tion was observed between nsBHR and the magnitude of
the FDC response to bronchodilator at f60. Mean
bronchodilator response of Cdyn,1/Cst,1 at f60 was 145%
for the group with nsBHR and 374% for the group
without nsBHR (P=002). Using the cutpoint of 15%
improvement, FDC response to bronchodilator at f60 was
present in 30% of subjects with nsBHR and 89% of those
without nsBHR (Fisher’s exact P=002).
Irritant-exposed and non-exposed groups appeared
similar on measures of Cst,1, Cdyn,1/Cst,1 at all three
respiratory frequencies, and proportion of subjects with
nsBHR (Table 3 and Fig. 1). No dierence was apparent
between individuals with RADS and those who were
exposed to relatively lower levels of irritants.
Six of the 12 irritant-exposed patients returned for
follow-up studies 7–34 months after complete elimination
or reduction of their exposure and treatment with inhaled
steroids. This group included two of the patients with
RADS, who were evaluated 21 and 34 months after their
index exposure episode. All six patients reported partial
resolution of their symptoms over time. Follow-up non-
specific bronchoprovocation demonstrated reversal of
nsBHR in four (including two of the subjects with RADS),
FIG. 2. The mean values (+ SE) of static (Cst,1) and
dynamic (Cdyn,1) compliance at each respiratory
frequency are plotted for the 19 subjects who had
measurements pre-bronchodilator (*) and post-
bronchodilator (*). The % increase in Cdyn,1/Cst,1 (with
95% confidence interval) is indicated above for each
respiratory frequency. * indicates P50001.
224 R. E. DE LA HOZ ET AL.a 4-fold increase in PC20 in one patient, and no change in
one patient without nsBHR at baseline. All six patients,
however, had persistent and unchanged frequency depen-
dent compliance on repeat testing (P=036).TABLE 3. Comparison of irritant-exposed (n=12) and unexposed
Variable

Cst,1, l cm
71 H2O 0177+003
Cdyn,1/Cst,1 at fBL (%) 79+14
Cdyn,1/Cst,1 at f40 (%) 61+13
Cdyn,1/Cst,1 at f60 (%) 47+11
Cdyn,1/Cst,1 at fBL, post-BD (%) 81+15
Cdyn,1/Cst,1 at f40, post-BD (%) 71+17
Cdyn,1/Cst,1 at f60, post-BD (%) 58+12
Bronchial hyper-reactivity (n) 7/12
*Data are provided as means+1SD.Discussion
This study demonstrated abnormal airway function, as
assessed by FDC, in all 22 subjects. Since nsBHR was
demonstrated in only 12 of these subjects, FDC was the
only detectable physiological abnormality in the remaining
10. Partial reversal of FDC in response to an inhaled
bronchodilator was more evident at the highest frequency
(f60) and in subjects without nsBHR. Comparisons
between irritant-exposed and non-exposed subjects revealed
similar FDC, FDC response to bronchodilator, and nsBHR
Although the sample size limited the statistical power to
detect dierences between these two groups, the overlap in
their test results (and with those of the three individuals
who met current criteria for RADS) suggests that they are
functionally similar. FDC has been recognized as a feature
of non-specific obstructive airway disease. These data
suggest that peripheral airway dysfunction may be a
frequently overlooked feature in individuals who have
persistent and unexplained respiratory symptoms, or who
have been exposed to irritants over a wide range of
concentrations.
Some methodological aspects deserve comment. The
study design was best suited for a comparison of the
findings of a widely used test (non-specific bronchoprovo-
cation) with those of a technically demanding test (FDC)
with limited availability. Despite some suggestion that FDC
may be the more sensitive test of small airway function
(7,32), controlled studies are warranted using measure-
ments derived from single-breath nitrogen washout or
helium–oxygen flow–volume curves, or frequency depen-
dence of resistance (33). Using a maximal expiratory
maneuver to assess nsBHR, although in widespread clinical
use, may have underestimated the presence of nsBHR in
our subjects (34,35), particularly since study entry criteria in
all likelihood selected individuals with less severe airway
obstruction (36).
For subjects in the current study, FDC was manifest over
a range of respiratory frequencies from fBL to f60. The
eects of peripheral airway obstruction on Cdyn,1 manifest(n=10) patients in the study*
Irritant exposure
7 P
6 0170+0057 071
74+14 038
58+15 064
45+13 064
83+13 078
72+18 090
54+13 050
5/10 100
FIG. 3. The observed values for Cdyn,1/Cst,1 at f60 for all
study subjects are plotted as a function of age. The shaded
area represents the 95% tolerance interval reported by
Begin et al. (40). 20/22 subjects had values for Cdyn,1/Cst,1
at f60 that were below the 95% tolerance interval reported
by Begin et al. Note, since two subjects had identical
values, only 21 data points are illustrated.
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frequencies (2,3,6,7). A decrease of Cdyn,1 at baseline
respiratory rate has been observed occasionally in chronic
bronchitis (2), in asthma early during recovery from an
acute attack of bronchospasm (37), in nitrogen dioxide
inhalation injury (17), as well as other lung diseases (38).
The observed variability of FDC and its response to
bronchodilator likely reflects a spectrum of airway
abnormality ranging in severity and anatomic location.
The response of FDC to inhaled bronchodilator was
variable across subjects and manifested at varying respira-
tory frequencies. Although some subjects demonstrated a
post-bronchodilator improvement in Cdyn,1 at fBL, the
improvement was more marked and consistent at f40 and
f60. This improvement of FDC after inhaled bronchodi-
lator is compatible with the observation that peripheral
airways, including those with a diameter of less than 2 mm,
have smooth muscle (39), which responds to histamine and
isoproterenol (40), and that FDC can be induced in
response to intravenous histamine (20).
Inhaled bronchodilator paradoxically worsened FDC in
approximately 25% of subjects at fBL, but not at higher
frequencies. These data are in accord with the observations
of Woolcock et al., who postulated that smooth muscle
tone in the peripheral airways may act to reduce variations
in time constants between lung units (2). Accordingly,
administration of a bronchodilator may interfere with this
adaptive phenomenon and lead to increased FDC.
The observed inverse association between nsBHR and
the magnitude of the FDC response to BD was an
unexpected finding. One possible explanation is a more
eective deposition of inhaled BD in the peripheral airways
of individuals with lesser degrees (or lack) of nsBHR. In a
recent study, Wagner et al. (40) directly measured
peripheral airway resistance and inhaled bronchodilator
response in asthmatic (all with nsBHR) and non-asthmatic
(all without nsBHR) subjects. They observed that inhaled
BD reverted a histamine induced increase in peripheral
airway resistance in their non-asthmatic (nsBHR7), but
not in their asthmatic (nsBHR) subjects. These observa-
tions may suggest that the predominant site of airway
hyper-responsiveness diers among patients with intermit-
tent obstructive disease and underline the limitations of
nsBHR as a predictor of peripheral airway physiologic
changes and responses. These observations clearly deserve
further investigation.
Asymptomatic cigarette smokers may demonstrate FDC
or other markers of peripheral airway dysfunction
(2,6,7,9,41). These physiological abnormalities have been
shown to correlate with peripheral airways changes in some
(41), and to be reversible after smoking cessation in others
(6). In contrast, clinical symptoms and bronchial hyper-
reactivity may persist in individuals with occupational
asthma despite exposure removal with or without inhaled
steroid treatment (42). In the current study, follow-up
evaluation of irritant-exposed subjects revealed persistent
FDC despite elimination or reduction of irritant exposure,
inhaled corticosteroid treatment, partial improvement of
symptoms and improvement in nsBHR. This finding, as
well as that of persistent FDC after bronchodilator in allsubjects, may reflect chronic inflammatory and/or structur-
al changes in the airways (2,6,39). This could be consistent
with the morphological changes described in individuals
with obstructive airway desease of diverse etiologies
(13,14,39,41,43).
Normal asymptomatic subjects may occasionally demon-
strate FDC. Although FDC may reflect a more complex
model, any physiological system with a resistance and
elastance in series will demonstrate frequency dependence
beyond a critical point. This has confounded the definition
of an abnormal FDC. Whereas the majority of studies have
indicated that values of Cdyn,1/Cst,1 at f60580% are
abnormal and define small airways dysfunction (2,6–
9,15,20,44), other studies have reported greater degrees of
FDC in a minority of asymptomatic subjects (4,45). This
finding may be attributable to several factors. Small
airways disease may occur in the absence of clinical
symptoms. Some studies have included current or prior
smokers as normal subjects (4). In addition, Begin et al.
demonstrated an age-related mechanism for FDC in
normal subjects, attributable to an increase in Cst,1 without
concomitant change in Cdyn,1 (45). For subjects in the
current study it is likely that the observed FDC does reflect
abnormality. Subjects in the present study uniformly
226 R. E. DE LA HOZ ET AL.demonstrated greater FDC than has been observed in our
laboratory or reported in studies of normal subjects (2,4,6–
9,15,20,44,45). In addition, following bronchodilator ad-
ministration, Cdyn,1/Cst,1 at f60 improved an average of
26% indicating at least partial reversibility of FDC. Lastly,
in most subjects Cdyn,1/Cst,1 at f60 was below the age-
adjusted normal range reported by Begin et al. (45). This is
graphically presented in Fig. 3 which illustrates that 20/22
subjects had values for Cdyn,1/Cst,1 at f60 that were below
the 95% tolerance interval reported by Begin et al.
(indicated by the shaded area). Future studies to corrobo-
rate normative data for FDC and/or with control groups
are warranted.
Despite some remaining uncertainty as to the exact
location of its underlying abnormalities (20,37), FDC
clearly provides information about a segment of the
airways that is not suciently explored by routine PFT
measurements or non-specific bronchoprovocation.
In conclusion, FDC and its response to bronochodilator
provide objective physiological measures of an airway
abnormality which may provide a basis for clinical
symptoms. In the occupational setting, FDC may con-
tribute to the early detection, physiological characterization
and evaluation of impairment in cases of irritant-induced
airway injury (especially at relatively low exposure levels)
and asthma (44,46,47). In the primary care setting, the
concept of asthma as an inflammatory disorder which
includes structural and physiological abnormalities in the
peripheral airways suggests that tests of peripheral airway
function, such as FDC and its response to bronochodilator,
may have an important diagnostic and therapeutic role.
Acknowledgements
This work was founded in part by NIOSH Cooperative
Agreement Program U60-CCU212004-02, NHLBI grant
HL-03386, New York State Department of Health contract
C-009820 and NIEHS grant ES-00268. The authors want to
acknowledge Dr William N. Rom for his critical review of
the manuscript and Mr Jianping Huang for technical
support in database management and in the preparation of
the manuscript for publication.
References
1. Otis AB, McKerrow CB, Bartlett RA, et al. Mechanical
factors in distribution of pulmonary ventilation. J Appl
Physiol 1956; 8: 427–443.
2. Woolcock AJ, Vincent NJ, Macklem PT. Frequency
dependence of compliance as a test for obstruction in
the small airways. J Clin Invest 1969; 48: 1097–1106.
3. Mead J. The lung’s ‘‘quiet zone’’ [Editorial]. N Engl J
Med 1970; 282: 1318–1319.
4. Sharp JT, Sweany SK, van Lith P. Physiologic
observations in diuse pulmonary fibrosis and granu-
lomatosis. Am Rev Respir Dis 1966; 94: 316–331.5. Ingram RH, Schilder DP. Association of a decrease in
dynamic compliance with a change in gas distribution.
J Appl Physiol 1967; 23: 911–916.
6. Ingram RH, O’Cain CF. Frequency dependence of
compliance in apparently healthy smokers versus non-
smokers. Bull Europ Physiopath Resp 1971; 7: 195–210.
7. McFadden ER, Kiker R, Holmes B, deGroot WJ.
Small airway desease—an assessment of the tests of
peripheral airway function. Am J Med 1974; 57: 171–
182.
8. Levine G, Housley E, MacLeod P, Macklem PT. Gas
exchange abnormalities in mild bronchitis and asymp-
tomatic asthma. N Engl J Med 1970; 282: 1277–1282.
9. Cutillo AG, Perondi R, Turiel M, Bigler AH,
Watanabe S, Renzetti AD. Pulmonary resistance and
dynamic compliance as functions of respiratory fre-
quency. Respiration 1983; 44: 81–89.
10. Balmes JR. Acute pulmonary injury from hazardous
materials. In: Sullivan JB, Krieger GR, ed. Hazardous
Materials Toxicology. Clinical Principles of Environ-
mental Health. Batlimore: Williams & Wilkins, 1992,
pp. 425–432.
11. Blanc PD, Galbo M, Hiatt P, Olson KR, Balmes JR.
Symptoms, lung function, and airway responsiveness
following irritant inhalation. Chest 1993; 103: 1699–
1705.
12. Kennedy SM, Wright JL, Mullen JB, Pare´ PD, Hogg
JC. Pulmonary function and peripheral airway disease
in patients with mineral dust of fume exposure. Am Rev
Respir Dis 1985; 132: 1294–1299.
13. Wright JL. Inhalational lung injury causing bronchio-
litis. Clin Chest Med 1993; 14: 635–644.
14. Douglas WW, Colby TV. Fume-related bronchiolitis
obliterans. In: Epler GR, ed. Diseases of the Bronch-
ioles. New York: Raven Press, 1994, pp. 187–213.
15. Seaton A, Lapp NL, Morgan WKC. Lung mechanics
and frequency dependence of compliance in coal
miners. J Clin Invest 1972; 51: 1203–1211.
16. Harless KW, Watanable S, Renzetti AD, Jr. The acute
eects of chrysotile asbestos exposure on lung function.
Environ Res 1978; 16: 360–372.
17. Fleming GM, Chester EH, Montenegro HD. Dysfunc-
tion of small airways following pulmonary injury due
to nitrogen dioxide. Chest 1979; 75: 720–721.
18. Kass I, Zamel N, Dorby CA, Holzer M. Bronchiectasis
following ammonia burns of the respiratory tract — a
review of two cases. Chest 1972; 62: 282–285.
19. de la Hoz RE, Schlueter DP, Rom WN. Chronic lung
disease secondary to ammonia inhalation injury: a
report on three cases. Am J Ind Med 1996; 29: 209–214.
20. Bhansali PV, Irvin CG, Dempsey JA, Bush R, Webster
JG. Human pulmonary resistance: eect of frequency
and gas physical properties. J Appl Physiol 1979; 47:
161–168.
21. Alberts WM, do Pico GA. Reactive airways dysfunc-
tion syndrome. Chest 1996; 109: 1618–1626.
22. Knudosn RJ, Lebowitz MD, Holberg CJ, Burrows B.
Changes in the normal maximal expiratory flow–
volume curve with growth and aging. Am Rev Respir
Dis 1983; 127: 725–734.
COMPLIANCE AND EVALUATION OF UNEXPLAINED RESPIRATORY SYMPTOMS 22723. Goldman HI, Becklake MR. Respiratory function
tests: normal values at median altitudes and the
prediction of normal results. Am Rev Tuberc 1959; 79:
457–463.
24. Briscoe WA, Dubois AB. The relationship between
airway resistance, airway conductance, and lung
volumes in subjects of dierent age and body size. J
Clin Invest 1958; 37: 1279–1285.
25. Turner JM, Mead J, Wohl ME. Elasticity of human
lungs in relation to age. J Appl Physiol 1968; 25:
664–671.
26. Schlueter DP, Immekus J, Stead WW. Relationship
between maximal inspiratory pressure and total lung
capacity (coecient of retraction) in normal subjects
and in patients with emphysema, asthma, and diuse
pulmonary infiltration. Am Rev Respir Dis 1967; 96:
656–665.
27. Juniper EF, Frith PA, Dunnett C, Cockcroft DW,
Hargreave FE. Reproducibility and comparison of
responses to inhaled histamine and methacholine.
Thorax 1978; 33: 705–710.
28. Weiss ST, Tager IB, Weiss JW, Mun˜oz A, Speizer FE,
Ingram RH. Airways responsiveness in a population
sample of adults and children. Am Rev Respir Dis 1984;
129: 898–902.
29. SPSS for Windows version 6.1. Chicago, SPSS Inc.
1993.
30. Zar JH. Biostatistical Analysis. Upper Saddle River,
NJ: Prentice Hall, 1996, p. 1–662.
31. Peslin R, Hannhart B, Pino J. Impe´dance me´canique
thoraco-pulmonaire chez des sujets fumeurs et non-
fumeurs. Bull Europ Physiopath Resp 1981; 17: 93–105.
32. Hayes GB, Christiani DC. Measures of small airways
disease as predictors of chronic obstructive pulmonary
disease. Occup Med 1993; 8: 375–395.
33. Brochard L, Pelle G, De Palmas J, et al. Density
and frequency dependence of resistance in early
airway obstruction. Am Rev Respir Dis 1987; 135:
579–584.
34. Fish JE, Rosenthal RR, Batra G, et al. Airway
responses to methacholine in allergic and nonallergic
subjects. Am Rev Respir Dis 1976; 113: 579–586.
35. Orehek J, Nicoli MM, Delpierre S, Beaupre A.
Influence of the previous deep inspiration on the
spirometric measurement of provoked bronchocon-striction in asthma. Am Rev Respir Dis 1981; 123:
269–272.
36. Orehek J, Charpin D, Velardocchio JM, Grimaud C.
Bronchomotor eect of bronchoconstriction-induced
deep inspirations in asthamatics. Am Rev Respir Dis
1980; 121: 297–305.
37. McFadden ER, Lyons HA. Airway resistance and
uneven ventilation in bronchial asthma. J Appl Physiol
1968; 25: 365–370.
38. Derderian SS, Tellis CJ, Abbrecht PH, Welton RC,
Rajagopal KR. Pulmonary involvement in mixed
connective tissue disease. Chest 1985; 88: 45–48
39. Hogg JC. Pathology of asthma. J Allergy Clin Immunol
1993; 92: 1–5.
40. Wagner EM, Bleecker ER, Permutt S, Liu MC. Direct
assessment of small airways reactivity in human
subjects. Am J Respir Crit Care Med 1998; 157:
447–452.
41. Cosio MG, Ghezzo H, Hogg JC, et al. The relations
between structural changes in small airways and
pulmonary-function tests. N Engl J Med 1977; 298:
1277–1281.
42. Maestrelli P, De Marzo N, Saetta M, Boscaro M,
Fabbri LM, Mapp CE. Eects of inhaled beclometha-
sone on airway responsiveness in occupational asthma
— placebo-controlled study of subjects sensitized to
toluene diisocyanate. Am Rev Respir Dis 1993; 148:
407–412.
43. Carroll N, Elliot J, Morton A, James A. The structure
of large and small airways in nonfatal and fatal asthma.
Am Rev Respir Dis 1993; 147: 405–410.
44. Morgan WKC, Lapp NL, Morgan EJ. The early
detection of occupational lung disease. Br J Dis Chest
1974; 68: 75–85.
45. Begin R, Renzetti AD, Jr., Bigler AH, Watanabe S.
Flow and age dependence of airway closure and
dynamic compliance. J Appl Physiol 1975; 38:
199–207.
46. Dosman JA. Preventive diagnosis in occupational
pulmonary disease [Editorial]. Ann Intern Med 1975;
83: 274–276.
47. Kipen HM, Blume R, Hutt D. Asthma experience in an
occupational and environmental medicine clinic. Low-
dose reactive airways dysfunction syndrome. J Occup
Med 1994; 36: 1133–1137.
